On 9 July 2025, the European Parliament (EP) adopted a resolution pressing for sweeping reforms in the e-commerce and imports sector, with a focus on consumer protection, product regulation, and unfair competition.1 The resolution sets out a series of measures, including calling for the swift implementation of the Digital Product Passport (DPP), strengthened customs enforcement through reform of the Union Customs Code (UCC), and the removal of the EUR 150 customs duty exemption for low-value consignments. The resolution will now be put submitted to the European Council and the European Commission for consideration.
United States: The One Big Beautiful Bill Act (OBBBA) changes the capitalized interest rules under section 163(j)
The One Big Beautiful Bill Act makes three major changes to the interest deduction limitation provision of §163(j). Pub. L. No. 119-21, §70303, §70341 (July 4, 2025), applicable to taxable years beginning after December 31, 2024. This article reviews the three changes and then focuses on the new rule for capitalized interest.
United Kingdom: FCA publishes rules for new prospectus regime
The Financial Conduct Authority (FCA) has published a policy statement (PS25/9: New rules for the public offers and admissions to trading regime) under which it sets out the rules for the new regime that will apply in respect of prospectuses. This follows the consultation process the FCA undertook via the previous publication of consultation papers CP 25/2 and CP 24/12. The Public Offers and Admissions to Trading Regulations 2024 (POATRs) will replace the UK Prospectus Regulation (UKPR). The POATRs are generally in line with the proposals consulted on, with some modifications to reflect feedback from market participants. The new rules will come into effect on 19 January 2026.
European Union: EU restricts access of Chinese medical devices to the European market
For the first time, the European Commission completed an investigation under the International Procurement Instrument (IPI) and implemented measures to limit the participation of economic operators from non-EU countries – in this particular case, China – in the EU public procurement market. After EU suppliers of medical devices have arguably been denied fair access to Chinese government contract opportunities for years, the EU has now responded with Implementing Regulation (EU) 2025/1197 that requires contracting authorities/entities in all EU member states to exclude Chinese suppliers – and to a certain extent products manufactured in China – from larger public procurement contracts for medical devices.